Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer

ABSTRACT: Open-label phase 1b trial. Study treatment will be administered in 3 week cycles. There are two distinct parts in this study: * Part 1: Dose escalation from IMO-2055 * Part 2: Once a recommended phase 2 dose is found additional tolerability and pharmacodynamics will be explored

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2058515 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR